AAM releases ‘Voices of Access’ reportThe report from the Association for Accessible Medicines highlights the impact that accessible generic and biosimilar medicines have had on patients nationwide. Hikma debuts labetalol hydrochloride in dextrose injection, sodium chloride injectionLabetalol HCl injection, 100 mg/20 ml and 200 mg/40 ml vial had a market value of approximately $6 million in the 12 months ended March 2021, according to IQVIA. Glenmark intros generic Banzel Banzel tablets had a market value of $285.3 million for the 12-month period ended April 2021, according to IQVIA. Sandoz offers generic Remodulin for subcutaneous administration The introduction of the RG 3-ml Medication Cartridge has enabled subcutaneous administration of Sandoz's treprostinil injection for the first time. Zydus Cadila launches biosimilar Ujvira The launch marks the world’s first biosimilar antibody drug conjugate of trastuzumab emtansine. Natco receives FDA nod for 2 generics Natco received the Food and Drug Administration's green light for generic Revlimid and Zortress. Upsher-Smith, Rafarm intro generic Vigamox The moxifloxacin ophthalmic solution had a market value of approximately $34 million for the 12 months ended March 2021, according to IQVIA. Camber debuts generic Strattera Camber's generic Strattera provides a treatment for attention-deficit hyperactivity disorder. FDA clears Glenmark’s generic Firazyr Firazyr injection had a market value of roughly $223.4 million for the 12 months ended March 2021, according to IQVIA. AAM makes 2 key appointments Erik Komendant will assume the role of the Association for Accessible Medicines’ senior vice president of government affairs and Steven Selde will serve as director of the Biosimilars Council. First Previous 120 121 122 123 124 Next Last
